论文部分内容阅读
本刊讯近日,北京大学人民医院肝病研究所魏来教授团队建立我国首个基于网络的多中心丙型肝炎临床数据和标本管理的平台,建立起难治性丙型肝炎优化治疗方案,使治愈率提高了20%。该团队的项目“我国慢性丙型肝炎临床转归、干预及治疗方案的优化”获得了“2015年中华医学科技奖二等奖”。据世界卫生组织统计,丙型肝炎病毒(HCV)感染呈全世界范围流行态势,全球慢性丙型肝炎病毒的感染率约为2.8%,估
Recently, Peking University People’s Hospital Institute of Liver Professor Wei Lai team to establish China’s first network-based multicenter clinical data and specimen management of hepatitis C platform to establish an optimal treatment of refractory hepatitis C to cure Rate increased by 20%. The team’s project “China’s clinical outcome of chronic hepatitis C, intervention and treatment program optimization ” won the “2015 China Medical Science and Technology Award second prize ”. According to the statistics of the World Health Organization, the prevalence of hepatitis C virus (HCV) infection is worldwide. The global infection rate of chronic hepatitis C virus is about 2.8%